Novocure Ltd (NASDAQ:NVCR) Announces Optune Will Be Available In 600 Locations In US


Novocure Ltd (NASDAQ:NVCR) has announced that Optune will now be accessible from more than 600 cancer treatment centers in the U.S.

The company announced yesterday that physicians at more than 600 US cancer treatment centers have been certified to prescribe the treatment to glioblastoma (GBM) patients. Optune is the firm’s wearable and portable delivery system for treating GBM that has been approved by the FDA under Tumor Treating Fields (TTFields). Novocure also stated that an additional 350 institutions have physicians that are certified to prescribe the delivery system to GBM patients.

“We are proud to have certified physicians at a variety of cancer treatment centers, both large and small, in the community and academic settings, nationally and worldwide,” stated Asaf Danzinger, the CEO of Novocure.

Novocure determined to widen Optune’s reach

Danzinger also pointed out that it was his company’s goal to make sure that the therapy is available to all GBM patients. He stated that Optune is now more accessible to GBM patients than it previously was and that Novocure is determine to widen its reach. The new certification is expected to make Optune more accessible especially to more communities as part of the company’s plan to reach a wider demography. This is also expected to lead to higher sales while also helping more patients.

According to Dr. Joseph C. Hodges, a certified Optune prescriber and radiation oncologist at Texas Oncology in Longview, Texas, Optune offers a lot of benefits to BGM patients. He also added that the cancer treatment center in which he is based is pleased to start prescribing the treatment to patients. Hodges stated that the oncology is interested in making sure that cancer patients have access to innovative treatments that will allow them to stay connected to their families and friends.

Optune is designed as a treatment for GBM patients that are above 22 years old and it is FDA-approved in the U.S. It is also approved in Japan for adult patients with supra-tentorial glioblastoma.

Novocure stock closed the latest trading session on Wednesday at $19.90 after tanking by 0.50 percent compared to the value of the stock during the previous close.

An ad to help with our costs